Covalent Bioscience's catabodies could transform Alzheimer’s treatment
Medium - 08-Apr-2023Company is seeking funds to advance from preclinical tests to human trials
Join the club for FREE to access the whole archive and other member benefits.
Open platform where individuals with unique perspectives share their thinking
he best ideas can change who we are. Medium is where those ideas take shape, take off, and spark powerful conversations. We’re an open platform where over 100 million readers come to find insightful and dynamic thinking. Here, expert and undiscovered voices alike dive into the heart of any topic and bring new ideas to the surface. Our purpose is to spread these ideas and deepen understanding of the world.
We’re creating a new model for digital publishing. One that supports nuance, complexity, and vital storytelling without giving in to the incentives of advertising. It’s an environment that’s open to everyone but promotes substance and authenticity. And it’s where deeper connections forged between readers and writers can lead to discovery and growth. Together with millions of collaborators, we’re building a trusted and vibrant ecosystem fueled by important ideas and the people who think about them.
Visit website: https://medium.com/
Details last updated 04-Feb-2019
Company is seeking funds to advance from preclinical tests to human trials
Raised $18 million Series A funding to speed up ageing research
A breakthrough technology focusing on effective gene therapies for healthy longevity
Insights on longevity, neural, and immune adaptations are revealed by a lobster
I'm not sure survivable cryonics is an easier problem than ageing, but good to have a plan B
Education and funding are essential to enable radical life extension in the next 20 years
Juvenescence Ltd is making investments in the future of rejuvenation and life extension technology
This is what everybody is really dreaming of when we talk about robotic surgery! Babak Parviz de...